The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer

Wang, Weigang; Xu, Ximing; Tian, Bailing; Wang, Yan; Du, Liqing; Sun, Tao; Shi, Yuting; Zhao, Xianxian; Jing, Jiexian

doi:10.1016/j.cca.2017.04.023

Cited by 145 publications

(89 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As most of patients with stage IV did not receive surgical treatment and pathological features were known, patients with stage IV were excluded in our study. As reported by Wang’s group, serum CEA, CA125, and CA153 were found to be higher in metastatic breast cancer patients than breast cancer patients without metastasis . Thus, we can only conclude that CEA, CA153, and FER had low diagnostic accuracy for early‐stage breast cancer (stage I‐III).…”

Section: Discussionmentioning

confidence: 60%

The association of five preoperative serum tumor markers and pathological features in patients with breast cancer

Lian

Zhang

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

BackgroundThe utility of frequently used serum tumor markers in breast cancer remains controversial. The study aimed to investigate the role of preoperative carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), cancer antigen 153 (CA153), cancer antigen 724 (CA724), and ferritin (FER) in the management of breast cancer and their relationships with pathological features.MethodsA total of 804 patients with breast mass who underwent breast surgery and 305 healthy volunteers were enrolled. Preoperative serum levels of CEA, CA125, CA153, CA724, and FER were measured. And the pathological features of all the patients were recorded. The association of preoperative serum tumor markers and pathological features was analyzed.ResultsAmong the 804 patients, 355 were identified as malignant cases and 449 as benign cases. CEA, CA153, and FER of patients with breast cancer were higher than those of healthy volunteer group and patients with benign breast diseases. The area under curve (AUC) of CEA, CA153, and FER for distinguishing patients with breast cancer and subjects with non‐breast cancer was 0.688 (95% CI: 0.656‐0.721), 0.609 (95% CI: 0.574‐0.645), and 0.623 (95% CI: 0.586‐0.660), respectively. CA153 correlated with tumor size, node status, and TNM stage, whereas CA125 with node status. No statistic differences of the five markers were observed among the four molecular subtypes.ConclusionPreoperative levels of CEA, CA153, and FER exhibit low diagnostic accuracy for breast cancer (stage I‐III). CA153 correlates with tumor burden, suggesting its prognostic value. The five serum markers do not correlate with molecular subtypes.

show abstract

Section: Discussionmentioning

confidence: 60%

The association of five preoperative serum tumor markers and pathological features in patients with breast cancer

Lian

Zhang

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…As individual serum tumour markers have limitations in their accuracy, several combination assays examining multiple markers have been developed, spanning a wide variety of different cancer types . Due to the rarity of the disease, the current study was limited in the number of enrolled patients; however, through use of a CEA and CYFRA 21‐1 combination assay, we were able to improve the positivity rate of detecting metastatic EMPD, and also demonstrate the utility of this method for monitoring treatment responses in patients with metastatic disease.…”

Section: Discussionmentioning

confidence: 99%

“…CEA is a cell‐surface glycoprotein normally produced by the gastrointestinal tract during fetal development . Serum detection is regarded as a sensitive diagnostic marker for CEA, with significant implications for both treatment response and prognosis of several adenocarcinomas . Based on these observations, the applicability of serum CEA levels as a biomarker of EMPD has been examined.…”

mentioning

confidence: 95%

Serum cytokeratin 19 fragment 21‐1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget disease

et al. 2019

View full text Add to dashboard Cite

Summary Background Extramammary Paget disease (EMPD) is a rare intraepithelial adenocarcinoma affecting the genitals and axillary regions. As metastasis of these tumours is itself rare, solid disease management strategies have not been established. Serum carcinoembryonic antigen (CEA) and cytokeratin 19 fragment 21‐1 (CYFRA 21‐1) levels have been identified as candidate biomarkers for tumour progression in EMPD. Objectives To determine the accuracy of and the correlation between these markers in patients with EMPD. Methods Serum CEA and CYFRA 21‐1 levels were examined in 30 patients with EMPD treated at Keio University Hospital, and compared against clinical information. Both assays were performed at the time of diagnosis, during the postoperative observation period, and following systemic treatment in those with confirmed metastasis. Serum levels were then correlated with tumour progression status and treatment responses. Results Normal levels for both assays were observed in all 11 patients with primary localized disease (100%). In patients with metastatic disease the CEA positivity rate was 79% (15 of 19 patients), with a rate of 63% (12 of 19 patients) for CYFRA 21‐1. Changes in CEA and CYFRA 21‐1 levels were statistically independent; however, using a combined view, elevated levels of either marker improved the positivity rate to 95% (18 of 19 patients). Use of both markers also correlated well with treatment responses. Conclusions The combination of CEA and CYFRA 21‐1 is useful for predicting metastasis and treatment response in patients with EMPD, especially in those who only have elevation of a single marker. What's already known about this topic? Serum levels of carcinoembryonic antigen (CEA) and cytokine 19 fragment 21‐1 (CYFRA 21‐1) have been shown to be elevated in patients with extramammary Paget disease (EMPD). Elevation of serum CEA levels is associated with tumour progression of EMPD. A single small study reported that serum CYFRA 21‐1 levels are elevated in patients with EMPD with lymph node metastasis. What does this study add? Serum CEA and CYFRA 21‐1 were present in 79% and 63% of 19 cases of metastatic EMPD, respectively. Elevations of CEA and CYFRA 21‐1 were statistically independent. CEA and CYFRA 21‐1 combination assays were positive in 95% of cases of metastatic EMPD. What is the translational message? Combination assays with CEA and CYFRA 21‐1 are useful for monitoring treatment response in patients with metastatic EMPD, particularly in those with elevation of either marker.

show abstract

“…It is reported that tumor biomarkers play an important role in the diagnosis, monitoring, and prognosis of malignant tumors. [ 16 ] Based on the analysis, we successfully identified 3 biomarkers as the risk factors for predicting BM from CRC, including CEA, CA125, and ALP. They were helpful for early diagnosing BM and could reduce the radiation from X-ray for patients due to radiographic tests.…”

Section: Discussionmentioning

confidence: 99%

“…As a tumor marker, CEA was widely used in clinical diagnosis, therapy monitoring, and prognosis prediction of breast cancer. [ 16 ] It is also applies to patients with CRC. In previous study, Liu et al [ 21 ] revealed that a high CEA level in CRC patients with BM was prone to a poor prognosis.…”

Section: Discussionmentioning

confidence: 99%

The risk factors for bone metastases in patients with colorectal cancer

Cao

Liu

et al. 2018

Medicine

View full text Add to dashboard Cite

This retrospective analysis aim to evaluate the potential risk factors for bone metastases (BM) in patients who were diagnosed with colorectal cancer (CRC).A total of 2790 patients diagnosed with CRC between January 2006 and December 2016 were collected in this study. All patients were divided into 2 groups, BM and no BM. The associations between biomarkers (including age, gender, histopathological types, alkaline phosphatase (ALP), carcinoembryonic antigen (CEA), cancer antigen 125, and so on), and BM in patients with CRC were analyzed. All the analyses were conducted by SPSS software (version 22.0, SPSS, Chicago, IL).Of all patients, 74 (2.7%) were identified with BM. The level of serum ALP, CEA, and cancer antigen 125 in patients with BM were obviously higher than those without BM (P < .001, P = .005, and P < .001). And the cut-off values of ALP, CEA, and cancer antigen 125 were 85.5 U/L, 6.9 mmol/L, and 16.8 mmol/L, respectively.ALP, CEA, and cancer antigen 125 were identified as the independent risk factors for BM in patients with CRC.

show abstract

The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer

Cited by 145 publications

References 23 publications

The association of five preoperative serum tumor markers and pathological features in patients with breast cancer

The association of five preoperative serum tumor markers and pathological features in patients with breast cancer

Serum cytokeratin 19 fragment 21‐1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget disease

The risk factors for bone metastases in patients with colorectal cancer

Contact Info

Product

Resources

About